Ribociclib: New breast cancer drug drastically boosts survival rates

A drug that can slow the progression of advanced breast cancer has been shown for the first time to lengthen survival in women whose disease started before or during menopause, researchers reported on Saturday. 

In patients who took the drug along with a standard treatment, 70% were still alive 3 1/2 years later, compared with only 46% of those given the standard treatment alone. 

The standard treatment uses drugs to block the hormone estrogen or stop the body from making it, because estrogen feeds the growth of breast cancer in many patients. 

The drug used in the trial, ribociclib, is a targeted therapy, which blocks an enzyme that helps cancer grow. 

Post a comment